Altogether, the above results consolidate the molecular mechanism of RANBP2-associated HCC malignancy, whereby its downstream SUMO target CEBPα is fundamental for OGA inactivation and subsequent hyper-O-GlcNAcylation. The gene discussed is OGA; the disease is hepatocellular carcinoma.